Literature DB >> 14613995

Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.

Sun Jin Kim1, Marjorie Johnson, Kristen Koterba, Matthew H Herynk, Hisanori Uehara, Gary E Gallick.   

Abstract

PURPOSE: The expression of c-Met, the receptor protein tyrosine kinase for hepatocyte growth factor/scatter factor, frequently increases during prostate tumor progression. However, whether reduced c-Met expression inhibits tumor growth and metastasis has not been ascertained. EXPERIMENTAL
DESIGN: c-Met expression was reduced by infection of an adenovirus expressing a c-Met ribozyme into the highly metastatic human prostate cancer cell line PC3-LN4. In vitro, effects on c-Met, Akt, and extracellular signal-regulated kinase 1/2 expression and phosphorylation, Src expression and activity, and vascular endothelial growth factor expression were determined, as were effects on cell migration and invasion. Prostate tumor formation and metastasis to regional lymph nodes in nude mice were examined after both ex vivo and in vivo infection of cells.
RESULTS: Infection of PC3-LN4 cells with the Ad-c-Met-expressing ribozyme decreased steady-state c-Met levels, decreased Src kinase activity, decreased vascular endothelial growth factor expression, and decreased migration and invasion versus the pU1 (control) virus. Significant inhibition of tumorigenicity (histologically confirmed tumors in only 1 of 10 mice) and consequent lymph node metastasis were observed upon ex vivo infection of Ad-c-Met. Similarly, gene therapy experiments led to complete inhibition of tumor growth in 7 of 8 mice.
CONCLUSIONS: Reduction in c-Met expression substantially inhibits both tumor growth and lymph node metastasis of PC3-LN4 cells in orthotopic nude mouse models. Therefore, targeting the c-Met signaling pathways may be important in controlling tumor growth and metastasis in human prostate cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613995

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.

Authors:  Yongjun Jiao; Ping Zhao; Jin Zhu; Tessa Grabinski; Zhengqing Feng; Xiaohong Guan; R Scot Skinner; Milton D Gross; Rick V Hay; Hiroshi Tachibana; Brian Cao
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

Review 2.  Prognostic value of c-Met in colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Xiao-Feng Yu; Jian Zou; Zi-Hua Luo
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

4.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

5.  Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.

Authors:  Mandy J Binning; Toba Niazi; Carolyn A Pedone; Bachchu Lal; Charles G Eberhart; K Jin Kim; John Laterra; Daniel W Fults
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 6.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

7.  Efficacy of c-Met inhibitor for advanced prostate cancer.

Authors:  William H Tu; Chunfang Zhu; Curtis Clark; James G Christensen; Zijie Sun
Journal:  BMC Cancer       Date:  2010-10-14       Impact factor: 4.430

8.  AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.

Authors:  Jing Zhang; Serk In Park; Marlene C Artime; Justin M Summy; Ami N Shah; Joshua A Bomser; Andrea Dorfleutner; Daniel C Flynn; Gary E Gallick
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Pre-clinical Orthotopic Murine Model of Human Prostate Cancer.

Authors:  Varahram Shahryari; Hannah Nip; Sharanjot Saini; Altaf A Dar; Soichiro Yamamura; Yozo Mitsui; Melissa Colden; Nathan Bucay; Laura Z Tabatabai; Kirsten Greene; Guoren Deng; Yuichiro Tanaka; Rajvir Dahiya; Shahana Majid
Journal:  J Vis Exp       Date:  2016-08-29       Impact factor: 1.355

10.  SPARCL1 suppresses metastasis in prostate cancer.

Authors:  Yuzhu Xiang; Qingchao Qiu; Ming Jiang; Renjie Jin; Brian D Lehmann; Douglas W Strand; Bojana Jovanovic; David J DeGraff; Yi Zheng; Dina A Yousif; Christine Q Simmons; Thomas C Case; Jia Yi; Justin M Cates; John Virostko; Xiusheng He; Xunbo Jin; Simon W Hayward; Robert J Matusik; Alfred L George; Yajun Yi
Journal:  Mol Oncol       Date:  2013-07-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.